Quantamental Technologies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Quantamental Technologies’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$171K	Buy	+24,160	New	+$174K	0.16%	231
2022 Q3	–	Sell	-14,081	Closed	-$149K	–	504
2022 Q2	$149K	Buy	+14,081	New	+$145K	0.07%	369
2021 Q3	–	Sell	-10,195	Closed	-$161K	–	293
2021 Q2	$161K	Buy	+10,195	New	+$139K	0.14%	226
2020 Q1	–	Sell	-10,989	Closed	-$38K	–	139
2019 Q4	$38K	Hold	10,989	–	–	0.02%	410
2019 Q3	$31K	Sell	10,989 -400	-4%	-$1.24K	0.01%	1094
2019 Q2	$43K	Buy	+11,389	New	+$68.5K	0.02%	937

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Quantamental Technologies's BCRX Position: Q3 2023 in Review

Quantamental Technologies opened a new position in BioCryst Pharmaceuticals (BCRX) in Q3 2023: 24,160 shares worth $171K. The stake represents 0.16% of the portfolio and ranks #231 among its holdings. This is a return to the name: Quantamental Technologies previously reported a position in BCRX as recently as Q2 2022.

Quantamental Technologies first reported a position in BCRX in Q2 2019 and has held it in 6 quarters since. 233 funds tracked by Wall St. Rank hold BCRX as of Q3 2023.

Quantamental Technologies held 24,160 shares of BioCryst Pharmaceuticals worth $171K as of Q3 2023.
BioCryst Pharmaceuticals was a new Quantamental Technologies position in Q3 2023.
BioCryst Pharmaceuticals made up 0.16% of Quantamental Technologies's portfolio in Q3 2023, its #231 holding.
Quantamental Technologies first reported a position in BioCryst Pharmaceuticals in Q2 2019 and has held it in 6 quarters since.
233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2023.

Based on Quantamental Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.